Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Confirmed response rate will be reported as the number of participants achieving either a complete response or partial response (using RECIST v1.1) divided by the number of evaluable participants. In order for a participant to be a confirmed objective responder, they must achieve a PR or CR on consecutive evaluations, at least 4 weeks apart. Complete Response (CR): Disappearance of all target lesions and normalization of tumor biomarkers. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Two patients were deemed ineligible for this endpoint due to eligibility criteria not being met. Therefore, this endpoint is reported using 14 eligible patients.

→

secondary · POSTED

Progression Free Survival is defined as the time from registration to the earliest date of documentation of disease progression or death. The distribution of time to progression will be estimated using the method of Kaplan-Meier.

Two patients were deemed ineligible and were not included in this endpoint.

→

secondary · POSTED

Overall Survival is defined as the time from registration to death. The distribution of survival will be estimated using the method of Kaplan-MeierEstimated using Kaplan-Meier methodology.

Two patients were not eligible for this endpoint.

→

secondary · POSTED

Safety will be assessed in terms of the number of participants reporting grade 3 or higher adverse events as evaluated by Common Terminology Criteria for Adverse Events v4.0 (CTCAE).

All patients that started protocol treatment were included in this analysis.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id: NCT01604772
trial label: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 4
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0000
source section id
NCT01604772-om-0000
source outcome index
0
endpoint
Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1
endpoint definition
Confirmed response rate will be reported as the number of participants achieving either a complete response or partial response (using RECIST v1.1) divided by the number of evaluable participants. In order for a participant to be a confirmed objective responder, they must achieve a PR or CR on consecutive evaluations, at least 4 weeks apart. Complete Response (CR): Disappearance of all target lesions and normalization of tumor biomarkers. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
time origin
Up to 32 weeks
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Two patients were deemed ineligible for this endpoint due to eligibility criteria not being met. Therefore, this endpoint is reported using 14 eligible patients.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0001
source section id
NCT01604772-om-0001
source outcome index
1
endpoint
Median Progression Free Survival
endpoint definition
Progression Free Survival is defined as the time from registration to the earliest date of documentation of disease progression or death. The distribution of time to progression will be estimated using the method of Kaplan-Meier.
time origin
Time of study entry to progression or death, up to 3 years after registration
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Two patients were deemed ineligible and were not included in this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0002
source section id
NCT01604772-om-0002
source outcome index
2
endpoint
Overall Survival
endpoint definition
Overall Survival is defined as the time from registration to death. The distribution of survival will be estimated using the method of Kaplan-MeierEstimated using Kaplan-Meier methodology.
time origin
Time of study entry to death due to any cause, assessed up to 3 years from registration
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Two patients were not eligible for this endpoint.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0003
source section id
NCT01604772-om-0003
source outcome index
3
endpoint
Incidence of Toxicities of Akt Inhibitor MK-2206
endpoint definition
Safety will be assessed in terms of the number of participants reporting grade 3 or higher adverse events as evaluated by Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
time origin
Time to first treatment to up to 30 days after completion of treatment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
All patients that started protocol treatment were included in this analysis.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0000
arm key
OG000
arm label
Treatment (Akt Inhibitor MK2206)
regimen
Treatment (Akt Inhibitor MK2206)
analyzed count
14
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01604772-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0001
arm key
OG000
arm label
Treatment (Akt Inhibitor MK2206)
regimen
Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO
analyzed count
14
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01604772-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0002
arm key
OG000
arm label
Treatment (Akt Inhibitor MK2206)
regimen
Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO
analyzed count
14
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01604772-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
outcome key
om-0003
arm key
OG000
arm label
Treatment (Akt Inhibitor MK2206)
regimen
Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Akt Inhibitor MK2206: 150 mg given PO
analyzed count
16
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01604772-om-0003#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-stage-ivc-major-salivary-gland-cancer-ajcc-v7
nct id
NCT01604772
harm key
EG000
source section id
NCT01604772-ae
event group key
EG000
event group label
Treatment (Akt Inhibitor MK2206)
serious affected
2
serious at risk
16
other affected
16
other at risk
16
frequency threshold
0
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice